NasdaqGS - Delayed Quote USD

Opthea Limited (OPT)

5.07

+0.06

+(1.20%)

At close: January 29 at 4:00:00 PM EST

Why Opthea (OPT) Is Among the Best Australian Stocks to Buy Now?

We recently compiled a list of the 10 Best Australian Stocks to Buy Now. In this article, we are going to take a look at where Opthea Limited (NASDAQ:OPT) stands against other best Australian stocks to buy now. According to a report by Vanguard published on January 24, Australia’s economy is expected to experience a gradual […]

Insider Monkey 2 days ago

OPT.AX
Top 3 Australian High Growth Tech Stocks to Watch

The Australian market has recently experienced a downturn, with the ASX200 down 0.6% at 8,280 points amid concerns over upcoming US jobs data and broader global economic uncertainties. In this challenging environment where nearly all sectors are showing declines, identifying high-growth tech stocks can be crucial for investors seeking opportunities; these companies often demonstrate resilience and potential through innovation and strategic positioning despite broader market volatility.

Simply Wall St. 20 days ago

NXLLF

CKDXF

OPT
+1.20%
Opthea to Host Investor Days in New York and Australia

Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on February 3 and Melbourne on February 5 MELBOURNE, Australia and PRINCETON, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl

GlobeNewswire 21 days ago

CKDXF

OPT
+1.20%
Opthea Announces Publication in Diabetic Macular Edema

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational Vision Science & Technology and included in the Anti-VEGF Special Journal Issue of ARVO DME program to be advanced after wet AMD topline data readout anticipated for COAST in early CY Q2 2025 and ShORe in mid-2025 MELBOURNE, Australia and PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limit

GlobeNewswire 22 days ago

CKDXF

OPT
+1.20%
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), t

GlobeNewswire last month

CKDXF

OPT
+1.20%
High Growth Tech Stocks To Watch In Australia December 2024

As the Australian market navigates a mixed landscape with the ASX200 slightly down by 0.2% and a tight labor market reflected in an unemployment rate of 3.9%, sectors like Information Technology are showing resilience with modest gains amidst broader economic challenges. In this environment, identifying high growth tech stocks involves looking for companies that can leverage innovation and adaptability to capitalize on emerging opportunities, particularly as certain sectors like Energy and...

Simply Wall St. last month

NXLLF

CKDXF

OPT
+1.20%
Opthea’s Wet AMD Program to be Featured at FLORetina 2024

MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLOReti

GlobeNewswire 2 months ago

CKDXF

OPT
+1.20%
Opthea to Participate in Citi 2024 Global Healthcare Conference

MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Glob

GlobeNewswire 2 months ago

CKDXF

OPT
+1.20%
Opthea Appoints Kathy Connell to Board of Directors

Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced th

GlobeNewswire 2 months ago

CKDXF

OPT
+1.20%
High Growth Tech Stocks in Australia for November 2024

As the Australian market faces a slight downturn with the ASX200 down 1.1% and sectors like Financials and Health Care underperforming, investors are keeping a close eye on economic indicators such as the wage price index, which has shown modest growth. In this environment, identifying high-growth tech stocks becomes crucial as these companies often have the potential to outperform due to their innovative capabilities and adaptability in fluctuating market conditions.

Simply Wall St. 2 months ago

CKDXF

OPT
+1.20%
XROLF
Opthea’s Wet AMD Program Featured at Ophthalmology Events

17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024 Ophthalmology Innovation Summit XIV, November 23, 2024 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Opthea and soziniberce

GlobeNewswire 2 months ago

CKDXF

OPT
+1.20%
Opthea to Participate in November Investor Conferences

Virtual Bell Potter Healthcare Conference, November 18, 2024 Jefferies London Healthcare Conference, November 19, 2024 MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two in

GlobeNewswire 2 months ago

CKDXF

OPT
+1.20%
Is Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts?

In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let’s look at where Opthea Limited (OPT) stands against other penny stocks with the biggest upside potential. Why Are Rate Cuts Good for Small Caps? The Federal Reserve slashed interest rates by a half point in September, kickstarting […]

Insider Monkey 3 months ago

OPT.AX
Opthea Files Notice of Annual General Meeting

Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s innovation agenda MELBOURNE, Australia and PRINCETON, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-relat

GlobeNewswire 3 months ago

CKDXF

OPT
+1.20%
Opthea Wet AMD Program to be Presented at Innovate Retina

MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois. David Boyer, MD, will present an update on

GlobeNewswire 3 months ago

CKDXF

OPT
+1.20%
High Growth Tech Stocks in Australia to Watch

Over the last 7 days, the Australian market has remained flat, yet it is up 16% over the past year with earnings forecasted to grow by 12% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability within a stable economic environment.

Simply Wall St. 3 months ago

CKDXF

OPT
+1.20%
RPGRF
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company con

GlobeNewswire 3 months ago

CKDXF

OPT
+1.20%
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in a fireside chat and be available for one-on-one investor meetings at the UBS Virtual Ophthalmology Day 2024 being held on Oc

GlobeNewswire 3 months ago

CKDXF

OPT
+1.20%
Opthea Joins the S&P/ASX 300 Index

MELBOURNE, Australia and PRINCETON, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that the Company joins the S&P/ASX 300 Index, effective Monday, September 23, 2024, prior to market open in Australia. “Opthea’s addition to the S&P/ASX 300 Ind

GlobeNewswire 4 months ago

CKDXF

OPT
+1.20%
Opthea (OPT): Biopharma Innovator on the Verge of a Wet AMD Treatment Revolution

We recently published a list of 7 Best ASX Stocks To Invest In Right Now. In this article, we are going to take a look at where Opthea (NASDAQ:OPT) stands against other ASX stocks to invest in right now. Overview of the Australian Economy According to a report by the Australian Bureau of Statistics, Australia’s […]

Insider Monkey 4 months ago

OPT.AX

Performance Overview

Return	OPT	S&P/ASX 200 [XJO]
YTD	+31.01%	+4.10%
1-Year	+99.61%	+11.76%
3-Year	-22.24%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Opthea Limited (OPT)

Why Opthea (OPT) Is Among the Best Australian Stocks to Buy Now?

Top 3 Australian High Growth Tech Stocks to Watch

Opthea to Host Investor Days in New York and Australia

Opthea Announces Publication in Diabetic Macular Edema

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

High Growth Tech Stocks To Watch In Australia December 2024

Opthea’s Wet AMD Program to be Featured at FLORetina 2024

Opthea to Participate in Citi 2024 Global Healthcare Conference

Opthea Appoints Kathy Connell to Board of Directors

High Growth Tech Stocks in Australia for November 2024

Opthea’s Wet AMD Program Featured at Ophthalmology Events

Opthea to Participate in November Investor Conferences

Is Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts?

Opthea Files Notice of Annual General Meeting

Opthea Wet AMD Program to be Presented at Innovate Retina

High Growth Tech Stocks in Australia to Watch

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

Opthea Joins the S&P/ASX 300 Index

Opthea (OPT): Biopharma Innovator on the Verge of a Wet AMD Treatment Revolution

Performance Overview